Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

description of historical facts are forward-looking statements, including without limitation all statements related to the development and potential approval and commercialization of fidaxomicin, expectations of Optimer's capital requirements to fund future operations, the timing of any review of regulatory submissions, the timing of any financial guidance for 2011, and the potential commercialization of fidaxomicin or payment of milestones or royalties by Astellas. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, uncertainty regarding regulatory requirements for approval and the timing of regulatory approvals, whether the FDA or other regulatory authorities will meet their goals for reviewing Optimer's regulatory submissions, Optimer's ability to recognize anticipated benefits from its collaboration with Astellas, the costs and timing of commercializing fidaxomicin in the U.S., if approved, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & SVP Finance858-909-0736Canale CommunicationsJason I. Spark, Senior Vice President619-849-6005Optimer Pharmaceuticals, Inc. Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2010200920102009Revenues:Research grants

$
56,352$
208,652$
980,362$
792,644Collaborative rese
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
(Date:7/30/2015)... Calif. , July 30, 2015  Cleave ... and Trademark Office has granted the company a ... covering Cleave,s lead molecule CB-5083. This ... as inhibitors of p97," U.S. 9,062,026, allows for ... a first-in-class, highly selective oral inhibitor of p97, ...
(Date:7/30/2015)... Flexpoint Ford, a private equity firm focused ... that it has entered into a partnership with ... form Kastle Therapeutics, LLC (Kastle).  The new company, headquartered ... acquiring, developing and commercializing pharmaceuticals targeted toward diseases with ... therapies already approved for marketing, as well as clinical ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... DIEGO, Feb. 6, 2012   Neurelis, Inc. today announced ... (FDA) has cleared an Investigational New Drug application ... of NRL-1 for the treatment of acute breakthrough ... late 2011, Neurelis filed the IND based upon ...
... Association (PCMA) launched a new ad campaign in Oregon ... (PBMs).  The ad campaign – "That,s What PBMs ... , PBMs lower costs for employers, unions, and consumers ... , PBMs help patients make informed prescription drug decisions ...
Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2PCMA Launches New Oregon Ad Campaign: 'That's What PBMs Do' 2
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels & Wheels ... Waycross, Georgia. Start time will be 7:30 AM. The duathlon is a 2 mile run, ... swim in Laura Walker Lake, a 13 mile bike, and a 3 mile run. ...
(Date:7/31/2015)... ... July 31, 2015 , ... With the recent buzz ... individuals who remain undiagnosed, treatment options for patients are becoming more prevalent than ... therapy due to its overall lack of comfort and highly invasive nature, oral ...
(Date:7/30/2015)... FL (PRWEB) , ... July 31, 2015 , ... On ... first meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. ... the event of an overdose is largely perpetuating the heroin crisis in North Florida. ...
(Date:7/30/2015)... , ... July 30, 2015 , ... OSF Healthcare ... results from the 2015 Most Wired Survey conducted by Hospitals & Health Networks. This ... system owned and operated by The Sisters of the Third Order of St. ...
(Date:7/30/2015)... ... 2015 , ... In a meaningful ritual intended to symbolize a final farewell ... have created an addiction graveyard. Sharing this with the public comes at a unique ... Hudson . Hudson (1945-2015) fell in love with the desert when he moved from ...
Breaking Medicine News(10 mins):Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... , , WASHINGTON, July 31 ... for Tobacco-Free Kids: , , (Logo: ... D.C. Council has taken an important step to protect the District,s kids ... cigarette tax by 50 cents to $2.50 per pack - the seventh ...
... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
... , , , Campaign ... After 4 months of college students and others wrestling with ... picked two winners for its nationwide sign design contest. The victors ... who is entering law school this fall at the University of ...
... , ALBANY, N.Y., July 31 ... New York throughout the week of August 3 - 7 ... New Yorkers access information on programs that provide prescription medicines for ... 8.2 percent, compared to 5.2 percent a year ago, the ...
... , , Partnership for ... WASHINGTON, July 31 The House Energy and Commerce ... legislation that would prohibit cost-sharing to Medicaid patients for recommended ... was supported by Partnership for Prevention, the American College of ...
... WASHINGTON, July 31 Last night, U.S. Rep. Lois Capps ... H.R. 3200, that would specifically include abortion in the health care ... Council Action President Tony Perkins had this to say on the ... up: , , "It has been clear ...
Cached Medicine News:Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help New York Workers Hurt by Recession 3Health News:House Committee Approves Amendment Eliminating Cost-Sharing for Medicaid Preventive Services 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2
... pacing wire design offers reliable ... in the atrium and ventricle ... in one lead design. The ... ventricle are color-coded for easy ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: